Generic Medicine Info
Indications and Dosage
Adjunct in ophthalmic surgery
Adult: As 2% soln: Administer via intraocular injection.

Dry eye
Adult: As 0.3-2.5% soln/gel: Instill 1-2 drops into affected eye(s) tid or as needed.
Special Precautions
Patient w/ pre-existing glaucoma. Pregnancy and lactation.
Adverse Reactions
Ophthalmologic: Mild stinging, blurred vision, eye pain, foreign body sensation, eye irritation, ocular hyperaemia, post-op transient increase in intraocular pressure.
Patient Counseling Information
This drug may cause transient blurring of vision on instillation, if affected, do not drive or operate machinery. Remove contact lenses prior to admin and reinsert after 15 min.
Description: Hypromellose is a methyl and hydroxypropyl mixed ether of cellulose. It is used as artificial tears to prevent conjunctival and corneal damage due to impaired lacrimal secretions. It is also used as a visco-elastic agent by maintaining a deep chamber and allowing more efficient manipulation, hence, helps the vitreous face to be pushed back, thereby preventing formation of a post-operative flat chamber.
Store below 25°C. Protect from light.
MIMS Class
Ophthalmic Lubricants
Anon. Hydroxypropyl Methylcellulose. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/07/2017.

Buckingham R (ed). Hypromellose. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/07/2017.

Genteal Severe Gel (Novartis Pharmaceutical Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 12/07/2017.

Goniovisc Ophthalmic Lubricant 2.5% Solution/Drops (HUB Pharmaceuticals, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 12/07/2017.

Joint Formulary Committee. Hypromellose. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/07/2017.

Disclaimer: This information is independently developed by MIMS based on Hypromellose from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
  • GenTeal
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in